Page 172 - 89Zr-Immuno-PET:Towards a Clinical Tool to Guide Antibody-based Therapy in Cancer
P. 172

                                Chapter 8
(prevention of potential toxicity/additional development costs) may justify the patient burden and cost for additional scans in a limited number of patients in a phase I setting.
For a mAb which continues in further stages of drug development, in vivo- measurements of antibody concentrations in tissue and tumor can be of value for PK/PD modelling/dose optimization and response prediction to guide individualized treatment.
CONCLUSION
This study demonstrates how immuno-PET in early clinical drug development provides a non-invasive technique to quantify dose-dependent uptake in normal tissues, indicative of specific, target-mediated uptake.
ACKNOWLEDGEMENTS
We thank Ronald Boellaard (Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, The Netherlands/ Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands) for the PET analysis software and Mats Bergstrom (independent external imaging consultant, Uppsala, Sweden) for conceptual support. We thank Chantal Roth (Department of Medical Oncology, VU University Medical Center, Amsterdam, the Netherlands) for supporting patient inclusion. We thank the Dutch Cancer Society (grant VU 2013-5839 to YJ).
170



























































































   170   171   172   173   174